Objective To investigate the inhibition of Surgetake on peritoneal implantation of gastric cancer MGC-80 cells. Methods Animal experiment: BALB/c (nu/nu) athymic nude mice received implantation of gastric cancer MGC-80 cells for modeling. The Surgetake group was divided into two groups. Group 1 and group 2 received intraperitoneal injection of Surgetake (10 ml/kg) daily for continuous 10 days after and at 5 days after the implantation of gastric cancer MGC-80 cells. A normal saline blank control group was included in the study. the mortality and growth condition of peritoneal tumor nodules of the mice were determined. Cytological study:the tumor cells were cen-trifuged, resuspended and cultured at 60 minutes after transient surface treatment with different concentrations of Sur-getake. The apoptosis, proliferation and cell cycle distribution were determined at baseline (control group), and at 24 h, 48 h and 72 h after Surgetake treatment, respectively. Results Animal experiment: compared with the control group, Surgetake could significantly inhibit the implantation effect of gastric cancer MGC-803 cells. The number of tu-mors in the study group 1 and 2 were significantly reduced by 49.4%and 61.0%, respectively ( P<0.05). The maxi-mum tumor diameter in the study group 1 and 2 were significantly reduced by 47.7% and 40.0% ( P<0.01). The mor-tality at 31 days after modeling: all mice in the study group survived, whereas all mice in the control group died from cancer. Cytological study: after removing the Surgetake transient cell membrane treatment, the proliferation of tumor cells was significantly decreased compared with that in the control group. At 72 h after 50%Surgetake transient cell membrane treatment, the proliferation A value in the study group was lower than that in the control group by 53.9%(0.41 vs 0.89). It was positively correlated with the Surgetake concentration, and was not invalid with the removal of the conditions. The G1 phase cell ratio in all Surgetake group and the control group was significantly increased (P<0.01). The apoptosis rate was significantly increased from (2.270±0.004)%at the baseline to (28.600±0.021)%at 72 hours. It was positively correlated with the treatment concentration, and was not invalid with the removal of the condi-tions. Conclusion Surgetake can inhibit implantation of exfoliated gastric cancer cells.%目的 探讨羧艾泰克生物胶体液(Surgetake)对胃癌MGC-80细胞腹腔种植的抑制作用.方法 动物实验:BALB/c(nu/nu)无胸腺裸鼠腹腔接种胃癌MGC-803细胞制作接种模型,Surgetake组分2组,实验组1接种肿瘤细胞后、实验组2接种5 d后,每天腹腔注射Surgetake(10 ml/kg),并设0.9%氯化钠注射液空白对照,连续10 d.观察动物死亡率、腹腔癌肿结节的生长状况.细胞学研究:不同浓度Surgetake一过性表面处理60 min后离心分离肿瘤细胞,重悬、培养,分别以处理前(对照组)与Surgetake处理后24、48、72 h,检测细胞凋亡、增殖与细胞周期分布情况.结果 动物实验:与对照组比较,Surgetake抑制胃癌MGC-803细胞种植的作用显著,实验组1、2瘤体数分别减少了49.4%、61.0%,差异具有统计学意义(P<0.05),实验组1、2最大肿瘤直径分别减少了47.7%、40.0%,差异具有统计学意义(P<0.01);造模后31 d,实验组全部存活,对照组因患瘤已经全部死亡.细胞学研究:Surgetake一过性细胞膜处理后条件移除后,与对照组比较肿瘤细胞增殖明显降低,50%Surgetake一过性处理后72 h实验组增殖吸光度(A)值为0.41,比对照组增殖降低了53.9%,对照组A值为0.89,与Surgetake处理浓度呈正相关,不随条件移除而失效;G1期细胞比率Surgetake各组与对照组比较,增加极为显著(P<0.01),凋亡率增加极为显著,由初始(2.270±0.004)%,72 h为(28.600±0.021)%,均与处理浓度呈正相关,不随条件移除而失去效能.结论 Surgetake具有抑制胃癌脱落细胞种植生长的作用.
展开▼
